Loading...
•
Sep 30, 2022
ALX Oncology Q3 2022 Earnings Report
Reported financial results and provided clinical development and operational highlights.
Key Takeaways
ALX Oncology reported its Q3 2022 financial results, highlighting the expansion of the clinical development of evorpacept and a new non-dilutive term loan facility expected to extend the company's cash runway to mid-2025.
Expanded clinical development of evorpacept with a new treatment arm in the I-SPY-P1 TRIAL.
ASH abstract released online with initial results of the Phase 1 dose escalation portion of ASPEN-05 study in AML.
Trials in Progress abstracts related to data from ASPEN-03 and ASPEN-04 clinical trials accepted for poster presentation at SITC.
Initiated a Phase 2 investigator-sponsored study of evorpacept in combination with ERBITUX and KEYTRUDA in patients with advanced colorectal cancer.
Forward Guidance
ALX Oncology believes its cash, cash equivalents, investments and the ability to draw down up to $50 million of its term loan are sufficient to fund planned operations through mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...